1 Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].CA, 2018, 68(6): 394-424.
2 Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM) [J]. Eur. J. Cancer, 2017, 4(75), 284-298.
3 Núñez C, Capelo JL, Igrejas G,et al. An overview of the effective combination therapies for the treatment of breast cancer[J]. Biomaterials, 2016, 97:34-50.
4 Ginsburg O, Bray F, Coleman MP, et al. The global burden of women’s cancers: a grand challenge in global health[J]. Lancet, 2016, 389(10071): 847-860
5 Justice RW, Zilian O, Woods DF, et al. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation [J]. Genes Dev, 1995, 9(5): 534-546.
6 Fu V, Plouffe S W, Guan K L. The Hippo pathway in organ development, homeostasis, and regeneration[J]. Current Opinion in Cell Biology, 2017, 49: 99-107.
7 Yao CB, Zhou X, Chen CS. The regulatory mechanisms and functional roles of the Hippo signaling pathway in breast cancer [J]. Yi Chuan, 2017, 39:617-629.
8 Vlug EJ, Van De Ven RAH, et al. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer [J]. Cell Oncol, 2013, 36(5):375-384.
9 Battaglia Parodi M, La Spina C, Berchicci L, et al. Photosensitizers and Photodynamic Therapy: Verteporfin[J]. Dev Ophthalmol, 2016, 55:330-336.
10 Liu-Chittenden, Y, Huang, B, Shim, J. S, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP[J]. Genes Dev, 2012, 26(12):1300-1305.
11 Wang C, Zhu X, Feng W, et al. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm[J]. Am J Cancer Res, 2015, 6(1):27-37.
12 Gibault F, Corvaisier M, Bailly F, et al. Non-photoinduced biological properties of Verteporfin[J]. Current Medicinal Chemistry, 2016, 23(11): 1171-84.
13 Neve R M, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.[J]. Cancer Cell, 2006, 10(6): 515-527.
14 Prat A, Cheang MC, Martín M, et al. Prognostic Significance of Progesterone Receptor Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer[J]. Journal of Clinical Oncology, 2013, 31(2): 203-209.
15 Network T C G A. Comprehensive molecular portraits of human breast tumours[J]. Nature, 2012, 490(7418):61-70.
16 Hart CD, Migliaccio I, Malorni L, et al. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer[J]. Nat Rev Clin Oncol, 2015, 12:541-552.
17 Dey N, De P. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials[J]. Pharmacol Ther, 2017, 175:91-106.
18 Fu V, Plouffe S W, Guan K L. The Hippo pathway in organ development, homeostasis, and regeneration[J]. Current Opinion in Cell Biology, 2017, 49: 99-107.
19 Yuhang Z, Tingting H, Alfred C, et al. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis[J]. International Journal of Molecular Sciences, 2016, 17(1):138-153.
20 Gjerdrum C, Tiron C, Hoiby T, et al. Axl is an essential epithelial- to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival[J]. Proceedings of the National Academy of Sciences, 2010, 107(3): 1124-1129.
21 Xie D, Nakachi K, Wang H et al. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features[J]. Cancer Res, 2001, 61(12): 8917-8923.
22 Yang, F. Stromal Expression of Connective Tissue Growth Factor Promotes Angiogenesis and Prostate Cancer Tumorigenesis[J]. Cancer Research, 2005, 65(19):8887-8895.
23 James Hutchenreuther1, Krista M Vincent2, David E Carter3, et al. CCN2 Expression By Tumor Stroma is Required for Melanoma Metastasis[J]. Journal of Investigative Dermatology, 2015, 135(11): 2805-2813.
24 Salvesen G S, Duckett C S. Apoptosis: IAP proteins: blocking the road to death's door[J]. Nat Rev Mol Cell Biol, 2002, 3(6): 401-410.
25 Peery R C, Liu J Y, Zhang J T. Targeting survivin for therapeutic discovery: past, present, and future promises[J]. Drug Discovery Today, 2017, 22(10): 1466-1477.
26 Chen Q, Zhang N, Gray RS, et al. A temporal requirement for Hippo signalling in mammary gland differentiation, growth and tumorigenesis. Genes Dev. 2014;28(5):432-437.
27 Rashidian J, Le Scolan E, Ji X, et al. Ski regulates Hippo and TAZ signalling to suppress breast cancer progression. Sci Signal. 2015;8(363):ra14.
28 Qin X, Li J, Sun J, et al. Low shear stress induces ERK nuclear localization and YAP activation to control the proliferation of breast cancer cells[J]. Biochem Biophys Res Commun, 2019, 510(2):219-223.
29 Li Y, Wang S, Wei X, et al. Role of inhibitor of yes-associated protein 1 in triple-negative breast cancer with taxol-based chemoresistance[J]. Cancer Science, 2019, 110(2):561-567.
30 Gibault F, Bailly F, Corvaisier M, et al. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway[J]. ChemMedChem, 2017, 12(12):954-961.
31 Ma Y W, Liu Y Z, Pan J X. Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation[J]. American Journal of Cancer Research, 2016, 6(12):2816-2830.
32 Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP[J]. Cancer Cell, 2014, 25(6):822-830.
33 Wei H, Wang F, Wang Y, et al. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex[J]. Cancer Science, 2017, 108(3):478-487.
34 Santucci M, Vignudelli T, Ferrari S, et al. The Hippo Pathway and YAP/TAZ–TEAD Protein–Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment[J]. Journal of Medicinal Chemistry, 2015, 58(12):4857-4873.
35 Lu T, Li Z, Yang Y, et al. The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer[J]. Cancer Letters, 2018, 423:36-46.
36 LiemT. Nguyen, MariaS. Tretiakova, Peter S, et al. ERG activates the YAP1 transcriptional program and induces the development of age-related prostate tumors[J]. Cancer Cell, 2015; 27:797-808.
37 Eckert RL, Kandasamy S, Adhikary G, et al. The YAP1 signaling inhibitors, verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype[J]. Mol Cancer Res, 2019, 11:1158/1541-7786.
38 Fu V, Plouffe S W, Guan K L. The Hippo pathway in organ development, homeostasis, and regeneration[J]. Current Opinion in Cell Biology, 2017, 49:99-107.
39 Jun L I, Lin Y E, Owen S, et al. Emerging role of CCN family proteins in tumorigenesis and cancer metastasis[J]. International Journal of Molecular Medicine, 2015, 36(6): 1451-1463.
40 Chien W, O'Kelly J, Lu D, et al. Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis[J]. International Journal of Oncology, 2013, 38(6): 1741-1747.
41 Zhang C, Luo X, Liu L, et al. Myocardin-related transcription factor A is up-regulated by 17β-estradiol and promotes migration of MCF-7 breast cancer cells via transactivation of MYL9 and CYR61[J]. Acta Biochimica Et Biophysica Sinica, 2013, 45(11): 921927.
42 Li MH, Sanchez T, Pappalardo A, et al. Induction of anti-proliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1-phosphate receptor 2[J]. Mol Cancer Res, 2008, 6:1649-1656.
43 Mahalingam S M, Ordaz J D, Low P S. Targeting of a Photosensitizer to the Mitochondrion Enhances the Potency of Photodynamic Therapy[J]. Acs Omega, 2018, 3(6):6066-6074.